219 related articles for article (PubMed ID: 15488791)
1. Analysis of irises with a latanoprost-induced change in iris color.
Arranz-Marquez E; Teus MA; Saornil MA; Mendez MC; Gil R
Am J Ophthalmol; 2004 Oct; 138(4):625-30. PubMed ID: 15488791
[TBL] [Abstract][Full Text] [Related]
2. Morphometric effects of long-term exposure to latanoprost.
Cracknell KP; Grierson I; Hogg P
Ophthalmology; 2007 May; 114(5):938-48. PubMed ID: 17292473
[TBL] [Abstract][Full Text] [Related]
3. Effect of age on the development of a latanoprost-induced increase in iris pigmentation.
Arranz-Marquez E; Teus MA
Ophthalmology; 2007 Jul; 114(7):1255-8. PubMed ID: 17306877
[TBL] [Abstract][Full Text] [Related]
4. A prospective study of iridial pigmentation and eyelash changes due to ophthalmic treatment with latanoprost.
Chiba T; Kashiwagi K; Ishijima K; Furuichi M; Kogure S; Abe K; Chiba N; Tsukahara S
Jpn J Ophthalmol; 2004; 48(2):141-7. PubMed ID: 15060793
[TBL] [Abstract][Full Text] [Related]
5. Latanoprost and pigmentation.
Grierson I; Jonsson M; Cracknell K
Jpn J Ophthalmol; 2004; 48(6):602-12. PubMed ID: 15592791
[TBL] [Abstract][Full Text] [Related]
6. Incidence and severity of iris pigmentation on latanoprost-treated glaucoma eyes.
Chou SY; Chou CK; Kuang TM; Hsu WM
Eye (Lond); 2005 Jul; 19(7):784-7. PubMed ID: 15359238
[TBL] [Abstract][Full Text] [Related]
7. A study of iridectomy histopathologic features of latanoprost- and non-latanoprost-treated patients.
Albert DM; Gangnon RE; Zimbric ML; Damico CM; Fisher MR; Gleiser J; Grossniklaus HE; Green WR
Arch Ophthalmol; 2004 Nov; 122(11):1680-5. PubMed ID: 15534130
[TBL] [Abstract][Full Text] [Related]
8. Increased iridial pigmentation in Chinese eyes after use of travoprost 0.004%.
Huang P; Zhong Z; Wu L; Liu W
J Glaucoma; 2009 Feb; 18(2):153-6. PubMed ID: 19225354
[TBL] [Abstract][Full Text] [Related]
9. Histology and fine structure of the iris and outflow system following latanoprost therapy.
Grierson I; Pfeiffer N; Cracknell KP; Appleton P
Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S176-84. PubMed ID: 12204715
[TBL] [Abstract][Full Text] [Related]
10. Fine structural evaluation of the iris after unilateral treatment with latanoprost in patients undergoing bilateral trabeculectomy (the Mainz II study).
Pfeiffer N; Grierson I; Goldsmith H; Appleton P; Hochgesand D; Winkgen A
Arch Ophthalmol; 2003 Jan; 121(1):23-31. PubMed ID: 12523881
[TBL] [Abstract][Full Text] [Related]
11. Monte Carlo simulation of latanoprost induced iris darkening.
Cracknell KP; Farnell DJ; Grierson I
Comput Methods Programs Biomed; 2007 Aug; 87(2):93-103. PubMed ID: 17576020
[TBL] [Abstract][Full Text] [Related]
12. A study of histopathological features of latanoprost-treated irides with or without darkening compared with non-latanoprost-treated irides.
Albert DM; Gangnon RE; Grossniklaus HE; Green WR; Darjatmoko S; Kulkarni AD
Arch Ophthalmol; 2008 May; 126(5):626-31. PubMed ID: 18474771
[TBL] [Abstract][Full Text] [Related]
13. Latanoprost-induced iris darkening: a morphometric study of human peripheral iridectomies.
Cracknell KP; Grierson I; Hogg P; Appleton P; Pfeiffer N
Exp Eye Res; 2003 Dec; 77(6):721-30. PubMed ID: 14609560
[TBL] [Abstract][Full Text] [Related]
14. Latanoprost-induced iris heterochromia and open-angle glaucoma: a clinicopathologic report.
Tsai JC; Sivak-Callcott JA; Haik BG; Zhang J; McLean IW
J Glaucoma; 2001 Oct; 10(5):411-3. PubMed ID: 11711840
[TBL] [Abstract][Full Text] [Related]
15. Iris morphology.
Teus MA; Arranz-Marquez E
Ophthalmology; 2008 Feb; 115(2):418-9; author reply 419-20. PubMed ID: 18243921
[No Abstract] [Full Text] [Related]
16. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color.
Wistrand PJ; Stjernschantz J; Olsson K
Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S129-38. PubMed ID: 9154289
[TBL] [Abstract][Full Text] [Related]
17. Increased pigmentation of iridial melanocytes in primates induced by a prostaglandin analogue.
Lindquist NG; Larsson BS; Stjernschantz J
Exp Eye Res; 1999 Oct; 69(4):431-6. PubMed ID: 10504276
[TBL] [Abstract][Full Text] [Related]
18. A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma.
Alm A; Schoenfelder J; McDermott J
Arch Ophthalmol; 2004 Jul; 122(7):957-65. PubMed ID: 15249358
[TBL] [Abstract][Full Text] [Related]
19. Iridial pigmentation induced by latanoprost ophthalmic solution in Japanese glaucoma patients.
Chiba T; Kashiwagi K; Kogure S; Abe K; Shibuya T; Furuichi M; Iijima H; Tsukahara S
J Glaucoma; 2001 Oct; 10(5):406-10. PubMed ID: 11711839
[TBL] [Abstract][Full Text] [Related]
20. Assessment of chamber angle pigmentation during longterm latanoprost treatment for open-angle glaucoma.
Nakamura Y; Nakamura Y; Morine-Shinjo S; Sakai H; Sawaguchi S
Acta Ophthalmol Scand; 2004 Apr; 82(2):158-60. PubMed ID: 15043533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
